# Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine

> **NCT04850625** · — · COMPLETED · sponsor: **Fudan University** · enrollment: 224 (actual)

## Conditions studied

- Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04850625
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-15
- **Primary completion:** 2021-06-15
- **Final completion:** 2021-06-15
- **Target enrollment:** 224 (ACTUAL)
- **Last updated:** 2022-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04850625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04850625, "Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04850625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*